TWO · 6620.TWO
Handa Pharmaceuticals, Inc.
NT$132.50-NT$5.00 (-3.64%)
Handa Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.52% below the high.
Loading market information…
TAI · 1707.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Grape King Bio Ltd’s quoted price sits in the lower half of its reported 52-week range, 36.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Grape King Bio Ltd’s forward annual dividend is NT$7.60 per share, paid semi-annual. The forward yield is 9.21% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Grape King Bio Ltd’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of NT$1.62. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Grape King Bio Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market presence spans Taiwan, mainland China, and various international regions. The company engages with customers through multiple operational avenues, including multi-level marketing channels, conventional distribution networks, and a significant original design and equipment manufacturing (ODM/OEM) division. Among its extensive product range are various mushroom mycelium derivatives, notably ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor. Additionally, it formulates and supplies probiotics featuring strains like enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium, alongside a selection of enzyme products. Beyond its own brand, Grape King Bio offers comprehensive contract services, such as original equipment manufacturing (OEM), original design manufacturing (ODM), custom formulation development, dedicated research and development support, and the provision of raw materials. Established in 1969, the firm maintains its corporate headquarters in Taoyuan City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 9, 2025 | NT$1.40-26.32% vs estimate | NT$2.25B-9.99% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | NT$3.02-16.11% vs estimate | NT$3.15B-9.63% vs estimate |
|---|
| Q3 2024 | Nov 11, 2024 | NT$2.80+15.23% vs estimate | NT$2.90B+7.34% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$132.50-NT$5.00 (-3.64%)
Handa Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.52% below the high.
NT$79.90-NT$0.50 (-0.62%)
TTY Biopharm Company Limited’s quoted price sits in the upper half of its reported 52-week range, 8.16% below the high.
NT$59.70-NT$0.10 (-0.17%)
YungShin Global Holding Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.71% below the high.
NT$20.00+NT$0.10 (+0.5%)
ScinoPharm Taiwan, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.27% below the high.
NT$28.80-NT$0.15 (-0.52%)
Synmosa Biopharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 8.54% below the high.
NT$57.40-NT$2.60 (-4.33%)
TaiMed Biologics Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.87% below the high.
NT$75.00-NT$0.80 (-1.06%)
Foresee Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.96% below the high.
NT$56.70-NT$0.20 (-0.35%)
Standard Chem & Pharm Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.36% below the high.
